In CRC, despite achieving initial responses, patients who originally present with no detectable mutations in KRAS (wild-type (WT) KRAS, or KRASWT, disease) develop acquired resistance to anti-EGFR therapy that is commonly driven by KRAS mutations, limiting the clinical benefit of this therapy13,17,18,19. This evidence concerns the gene EGFR and colorectal carcinoma.